Impact of Insulin Copay Cap Legislation on Savings, Adherence and Utilization Among Health Plan Medicare Beneficiaries

June 16, 2025

Rising insulin costs have created barriers to treatment adherence for Medicare beneficiaries, with one in four insulin users reporting that cost has led them to cut back or skip doses. The Inflation Reduction Act’s $35 insulin copay cap was designed to improve affordability and expand access to insulin therapy, while interest in GLP-1 therapies continues to grow. Understanding how lower out-of-pocket costs influence adherence, utilization and savings may help inform future strategies for managing diabetes care in Medicare populations.

Stay Informed and Connected

Receive expert insights, healthcare tips, and important updates on pharmacy benefits, drug recalls, and more—straight to your inbox.

CLARITY FOR ACTION

Gain Clarity: Navitus 10th Annual Drug Trend Report Ready to Download

Our 2025 report provides transparent, data-driven insight to help plans, plan sponsors and consultants navigate an increasingly complex prescription drug landscape.

Related blogs

Navigating Healthcare and Improving Outcomes